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predictive value of cervical 
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in high-risk women
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Donald Peebles2, Mona Bajaj-Elliott3, Nigel Klein3, Judith N. Bulmer1, Stephen C. Robson1 & 
Gendie E. Lash  1,5
Spontaneous preterm birth (sPTB, delivery <37 weeks gestation), accounts for approximately 10% of 
births worldwide; the aetiology is multifactorial with intra-amniotic infection being one contributing 
factor. This study aimed to determine whether asymptomatic women with a history of sPTB or cervical 
surgery have altered levels of inflammatory/antimicrobial mediators and/or microflora within cervical 
fluid at 22–24 weeks gestation. External cervical fluid was collected from women with history of 
previous sPTB and/or cervical surgery at 22–24 weeks gestation (n = 135). Cytokine and antimicrobial 
peptides were measured on a multiplex platform or by ELISA. qPCR was performed for detection of 
7 potentially pathogenic bacterial species. IL-8 and IL-1β levels were lower in women who delivered 
preterm compared to those who delivered at term (IL-8 P = 0.02; IL-1β P = 0.04). There were no 
differences in elafin or human beta defensin-1 protein levels between the two groups. Multiple bacterial 
species were detected in a higher proportion of women who delivered preterm than in those who 
delivered at term (P = 0.005). Cervical fluid IL-8 and IL-1β and microflora have the potential to be used as 
biomarkers to predict sPTB in high risk women.
Pre-term birth (PTB), defined as delivery before 37 completed weeks of gestation, accounts for approximately 
70% of neonatal deaths and is a major cause of neonatal morbidity including respiratory distress syndrome, 
necrotising enterocolitis and long-term neurological disabilities1,2. Worldwide there are 15 million preterm births 
every year (~1 in 10 of all births), with the annual rate increasing3–5. PTB may be related to spontaneous preterm 
labor (40–45%) or preterm prelabor rupture of membranes (25–30%), together classified as spontaneous PTB 
(sPTB), with the remaining preterm deliveries being indicated if either the mother or fetus is at risk2.
Spontaneous labor occurs following the activation of a pro-inflammatory ‘common pathway’ with increased 
cytokines and prostaglandins within myometrium, amniotic membranes and cervix leading to increased uterine 
contractility, rupture of membranes and cervical dilatation6. While this pathway is activated physiologically in 
term labor, it is postulated that one or more pathological processes (intra-amniotic infection (IAI), decidual 
haemorrhage, decidual senescence, disruption of maternal-fetal tolerance, decline in progesterone action, uterine 
over-distension and stress) may lead to activation of this pathway in preterm labor6. IAI is the only one which has 
been causally linked to sPTB; it is present in up to 30% of sPTB cases and in 60% of patients delivering before 28 
weeks gestation7,8. When bacteria are isolated from amniotic fluid in cases of PTB, they are similar to pathogenic 
bacteria found in the lower genital tract suggesting the most common mode of infection is via the vagina through 
the cervix and chorioamniotic membranes6,9–15. Presence of a greater spectrum of bacterial species is also asso-
ciated with sPTB, with 2 or more bacterial species being reported in over 60% of fetal membranes and placental 
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tissues sampled from patients delivering preterm15. The cervix acts as a barrier to ascending infection and IAI is 
found in more than 50% of women presenting with mid-trimester cervical dilatation16.
Accurate prediction of sPTB allows identification of high-risk women for whom appropriate interventions 
such as antibiotics, cervical cerclage or progesterone can be considered, with the aim of preventing sPTB and 
improving neonatal outcomes. Risk factors for sPTB include a previous history of sPTB, mid-trimester pregnancy 
loss or cervical surgery, and strategies for prediction include screening for bacterial vaginosis and serial trans-
vaginal ultrasound measurement of cervical length17–20. More recently biomarkers within cervicovaginal fluid 
(CVF) have been investigated as predictors of sPTB, including pro-inflammatory cytokines and natural antimi-
crobials such as elafin and human beta defensins (HBD), but the results have been variable with poor agreement 
between studies21–33. To date there is no established marker for predicting sPTB in asymptomatic patients. Fetal 
fibronectin assessment is becoming more widely used, but it is not yet recommended for use by ACOG or NICE 
guidelines34,35.
The aim of this study was to prospectively investigate whether asymptomatic women with a singleton preg-
nancy and a history of sPTB and/or cervical surgery had altered expression of cytokines and antimicrobial pep-
tides, and/or microflora within cervical fluid at 22–24 weeks gestation.
Materials and Methods
Subjects. One hundred and thirty-five women attending PTB clinics due to either a history of previous 
sPTB or one or more large loop excision of the transformation zone (LLETZ) of the cervix were recruited at 
the Newcastle upon Tyne Hospitals National Health Service Foundation Trust (Newcastle upon Tyne, UK). The 
study received ethical approval (County Durham & Tees Valley 2 Research Ethics Committee; 08/H0908/79), and 
all patients gave informed written consent. The study was performed according to all the relevant institutional 
guidelines and according to the Declaration of Helsinki. Women who were under 16 years of age, had a multiple 
pregnancy, did not speak English or who had active vaginal bleeding were excluded from the study. Exclusions 
were based on the patient’s ability to give informed consent and welfare. All women were screened (and where 
deemed clinically appropriate treated) for lower genital tract infection at booking (high vaginal swab for micros-
copy, culture and sensitivity) and cervical length was measured by transvaginal ultrasound at 18–23 weeks.
Sampling collection and processing. CVF and cells were collected from the external cervical os by gently 
rotating a Rovers® Cervex-Brush (Rovers Medical Devices, Lekstraat, The Netherlands) three times in the cervi-
cal canal during sterile speculum examination at 22–24 weeks gestation36. Following collection, cytobrush heads 
were cut in half with a sterile scalpel blade; one half was immediately suspended in 5 ml sterile phosphate-buffered 
saline (PBS) with 50 µl penicillin/streptomycin and 50µl L-glutamine, while the other half was stored in a dry pot 
at −20 °C. CVF was mixed well to disperse cells from the cytobrush head, centrifuged at 1800rpm for 10 minutes, 
supernatant collected and frozen at −80 °C.
Sample concentration and assessment of total protein concentration. CVF was concentrated 
using filter concentrators with a 3 kDa cut off (Millipore, Watford, UK) according to the manufacturer’s instruc-
tions. Total protein concentration was determined by Bio-Rad Protein Assay (Bio-Rad Laboratories, Hemel 
Hempstead, UK).
FAST quant multiplex arrays for cytokine analysis. FASTQuant Human II multiplex protein arrays 
for IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, GM-CSF, MCP-1 and RANTES were run according to the man-
ufacturer’s instructions (Whatman GE Healthcare, Sanford, ME, USA) as previously described37,38. The dynamic 
ranges for analytes were: 3–3000 pg/ml (IL-1β, IL-2, IL-6, GM-CSF), 4–3000 pg/ml (IL-4), 5–3000 pg/ml (MCP-1, 
RANTES), 10–3000 pg/ml (IL-8), 30–12000 pg/ml (IL-10, IL-12p70).
ELISA for elafin and HBD1-3. ELISA was performed in duplicate to assess levels of elafin (R&D Systems, 
Abingdon, UK) and HBD1-3 (Peprotech, London, UK) according to the manufacturer’s instructions. The 
dynamic ranges were 31.2–2,000 pg/mL (elafin), 4–1,000 pg/ml (HBD1), and 16–2,000 pg/ml (HBD2, HBD3).
DNA extraction and PCR. After thawing of the dry part of the cytobrush, 1000 µl PCR grade water 
(Sigma-Aldrich) was added to each container. After vortexing well, the fluid was aspirated, transferred to a sterile 
Eppendorf, and genomic DNA extracted using a QIAmp DNA Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instructions, with an additional bead-beating step to lyse bacterial cells using Lysing Matrix B 
and a FastPrep instrument (MP Biomedicals, Santa Ana, CA, USA) and a TissueLyser LT instrument. Samples 
were eluted in 200 µl UV irradiated AE (10 mM Tris-Cl, 0.5 mM EDTA). A negative control (200 µl UV irradiated 
buffer AE) was included in each extraction round.
Taqman PCR assays were carried out using the ABI Prism 700 detection system (Life Technologies, Paisley, 
UK). Each reaction consisted of QuantiTect Multiplex Mastermix with Rox Dye (Qiagen), primers and probe 
(final concentration of each 0.1 µM; Life Technologies; Table 1), 7 µl template DNA or control and PCR grade 
water to a final volume of 20 µl. Cycling conditions were: 50 °C for 2 min, 95 °C for 10 min and then 45 cycles of 
95 °C for 15 sec and 60 °C for 1 min. To control for adequate DNA extraction and amplification, a real-time PCR 
that detects human C-reactive protein was run for each sample. Human C-reactive protein DNA was amplified 
in all samples.
Placental pathology. After delivery, placentas were submitted for histopathological examination. Placentas 
were fixed in formalin for 48 hours, weighed and subjected to macroscopic examination for macroscopic evidence 
of chorioamnionitis, infarction or other lesions. Two blocks each were then taken from umbilical cord (close to 
the insertion and distally), reflected amniochorionic membranes and full thickness placental parenchyma to 
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include chorionic plate and basal plate, as well as any macroscopic lesions identified. Samples were routinely 
processed into paraffin wax and 4 µm sections were stained with haematoxylin and eosin and examined by an 
experienced placental histopathologist (JNB). Placentas were examined for features of chorioamnionitis, villi-
tis, vascular problems, placenta neoplasms such as chorangioma and miscellaneous lesions such as intervillous 
thrombus. Maternal and fetal inflammatory responses were staged and graded according to Redline et al.39, noting 
the presence or severity of chorionic vasculitis, umbilical vasculitis, subchorionitis and chorioamnionitis. Villitis 
was recognised by the presence of acute or chronic inflammatory cells in chorionic villous stroma. Evidence 
of maternal vascular underperfusion was recognised by a small placenta (<10th percentile), villous infarction, 
increased syncytial knots, villous agglutination, distal villous hypoplasia, increased villous cytotrophoblast, thick-
ened trophoblast basement membrane, increased intervillous fibrin and maternal vascular lesions such as acute 
atherosis and muscularised basal plate arteries40,41.
Statistical analysis. All cytokine, elafin and HBD levels were corrected for total protein and results pre-
sented as pg/mg total protein. Statistical analyses were performed using the Prism statistical software package. 
Data were checked for normality and considered to be not normally distributed. Significance between two groups 
was determined using Mann Whitney U Test for non-parametric data. Chi-squared analysis was used to deter-
mine the association between number of bacterial species and PTB. Differences were considered significant at 
P < 0.05. A Bonferroni correction was used where multiple analyses were being performed (bacterial species and 
cytokine analysis; bacterial species and PTB incidence) and differences were considered significant at P < 0.01.
Results
Demographics. Of the 135 patients recruited into the study, 92 had a history of previous preterm birth 
alone, 34 a history of cervical surgery alone and 9 a history of both previous preterm birth and cervical surgery. 
Demographic details of the women recruited into the study organised by inclusion criteria and birth outcome are 
Primer/probe Sequence
Fusobacterium spp.
forward 5′ GGA TTT ATT GGG CGT AAA GC 3′
reverse 5′ GGC ATT CCT ACA AAT ATC TAC GAA 3′
probe FAM 5′CTC TAC ACT TGT AGT TCC G 3′ TAMRA
Group B Streptococci
forward 5′ ATC CTG AGA CAA CAC TGA CA 3′
reverse 5′ TTG CTG GTG TTT CTA TTT TCA 3′
probe JOE 5′ ATC AGA AGA GTC ATA CTG CCA CTT 3′ TAMRA
Mycoplasma hominis
forward 5′ ATT GAT TGC TGC AGG TGA TAC A 3′
reverse 5′ GGT GTT ACA ATA TCA GCC CCA AC 3′
probe FAM 5′ AGA GCA GCG GCA GTT GAA 3′ TAMRA
Peptostreptococcus micros
forward 5′ GCC GTA AAC GATGAG TGC TAG G 3′
reverse 5′ CCA GGC GGA ATG CTT AGT GT 3′
probe FAM 5′ TGG GAG TCA AAT CTC GCC G 3′ TAMRA
Sneathia/Leptotricia
forward 5′ AAT TAT TGG GCT TAA AGG GCA TC 3′
Reverse (S) 5′ CTA CAA AAC TGT ATA ACT AGA GTA CT 3′
Reverse (L) 5′ CTA CAA AAC TGT TGA ACT AGA GTA C 3′
probe FAM 5′ ACA AGT TGA AGG TGA AAA CCT RTG GC 3′ TAMRA
Ureaplasma parvum
forward 5′CAT TGA TGT TGC ACA AGG AGA AA 3′
reverse 5′ TTA GCA CCA ACA TAA GGA GCT AAA TC 3′
probe FAM 5′ TTG ACC ACC CTT ACG AG 3′ TAMRA
Ureaplasma urealyticum
forward 5′ ATC GAC GTT GCC CAA GGG GA 3′
reverse 5′ TTA GCA CCA ACA TAA GGA GCT AAA TC 3′
probe JOE 5′ TTG TCC GCC TTT ACG AG 3′ TAMRA
Human C reactive protein
forward 5′ CTT GAC CAG CCT CTC TCA TGC 3′
Reverse 5′ TGA AGT AGA CCC CAC CC 3′
Probe JOE 5′ TTT GGC CAG ACA GGT AAG GGG CAC 3′ TAMRA
Table 1. Primer/probe sets used for 16s rDNA PCR.
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shown in Tables 2 and 3, respectively. Overall there were no statistically significant differences between the patient 
characteristics amongst the three groups of women recruited into the study.
Levels of cytokines (previous PTB n = 71, cervical surgery n = 14, previous PTB/cervical surgery n = 7; total 
n = 95), and elafin and HBD1-3 (previous PTB n = 91, cervical surgery n = 33, previous PTB/cervical surgery 
n = 8; total n = 132) were determined in CVF. Cervical microflora were analysed in 88 women (previous PTB 
n = 63, cervical surgery n = 21, previous PTB/cervical surgery n = 4). It was not possible to analyse all the ana-
lytes in all of the samples. There was insufficient volume of CVF after concentration in 3 samples and for others, 
analysis of antimicrobial factors was prioritised over analysis of cytokines. For cytokine analysis all women who 
delivered preterm were included; samples from women who delivered at term were taken randomly from the 
cohort to include representative numbers of those who had previous preterm birth or cervical surgery, or both. 
PCR analysis was performed on a reduced sample number due to a freezer failure leading to loss of dry cytobrush 
samples prior to bacterial DNA analysis.
Cervical fluid levels of cytokines, elafin and HBD1-3. Levels of IL-2, IL-4, IL-6, IL-10, IL-12p70, 
GM-CSF, MCP-1, RANTES, HBD2 and HBD3 in CVF were below the level of detection for the assay, despite con-
centration of the samples. The median (IQR; range) levels for cytokines, elafin and HBD1 are shown in Table 4. 
There were no differences between women who had previous sPTB or cervical surgery (data not shown).
IL-8 and IL-1β levels were reduced in women who delivered preterm (IL-8: 991.8 pg/mg protein; IL-1β: 
35.6 pg/mg protein) compared with those delivering at term (IL-8: 1472.4 pg/mg protein, P = 0.03; IL-1β: 66.7 pg/
mg protein; P = 0.04) (Fig. 1A,B).
Elafin and HBD1 levels did not differ between women who delivered preterm and those who delivered at term.
Variable
Previous preterm 
birth (n = 92)
Cervical surgery 
(n = 34)
Both previous preterm birth and 
cervical surgery (n = 9)
Age (years), median (range) 29 (17–44) 33.0 (25–39) 32.0 (29–36)
BMI (kg/m2), median (range) 26 (17–38) 25.5 (21–52) 25 (23–27)
Ethnicity, n (%)
White European 87 (94.5) 34 (100) 9 (100)
White/black Caribbean 1 (1.1) 0 (0) 0 (0)
Asian-British 1 (1.1) 0 (0) 0 (0)
Indian 2 (2.2) 0 (0) 0 (0)
Other – Philipino 1 (1.1) 0 (0) 0 (0)
Smoking status, n (%)
Yes 28 (30.4) 5 (14.7) 1 (11.1)
No 64 (69.6) 28 (82.4) 8 (88.9)
Not known 0 (0) 1 (2.9) 0 (0)
Parity, median (range) 1 (0–7) 0 (0–4) 2 (1–3)
Gestational age of previous PTB (completed weeks), mean 
(range) 31 (23–35) N/A 33 (27–35)
Randomised to Opptimum trial, n (%)
Yes 16 (17.4) 1 (2.9) 4 (44.5)
No 76 (82.6) 33 (97.1) 5 (55.6)
Cervical length measured, n (%)
Yes 54 (58.7) 15 (44.1) 5 (55.6)
No 38 (41.3) 19 (55.9) 4 (44.4)
Cervical length (mm), median (range) 31 (1–51) 30 (21–46) 36 (20–36)
Preterm birth (this pregnancy) n (%)
Yes 36 (39.1) 4 (11.7) 2 (22.2)
No 56 (60.9) 30 (88.3) 7 (77.8)
Gestational age at delivery (completed weeks), median 
(range) 38.0 (25–42) 39.0 (28–41) 38.0 (25–41)
Placental pathology, n (%)
No placental pathology 12 (13.0) 5 (14.7) 3 (33.3)
Chorioamnionitis 19 (20.7) 2 (5.9) 0 (0)
Other placental pathology 12 (13.0) 5 (14.7) 1 (11.1)
Placenta not available 49 (53.3) 22 (64.7) 5 (55.6)
Microflora measured, n (%)
Yes 63 (68.4) 21 (61.8) 4 (44.4)
No 29 (31.5) 13 (38.2) 5 (55.6)
Table 2. Demographics of total cohort of patients included in cervical fluid analysis.
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Cervical microflora. 27.9% more women with samples positive for Peptostreptococcus (95% CI 6.0–48.6, 
P = 0.005) delivered preterm than women with samples negative for these bacteria (Table 5). There was an asso-
ciation between preterm birth and the number of bacterial species detected. Fifty percent more women with four 
or more positive samples delivered preterm compared with women with no positive samples (95% CI 4.27–78.0, 
P = 0.009; Bonferroni alpha = 0.01; Fig. 2).
Cervical microflora and cytokine, elafin and HBD1 levels. Paired bacterial DNA samples and CVF 
were available for 45, 51, 81 or 87 women depending on analysis variables (Table 6). In women who tested posi-
tive for Fusobacterium species median levels of IL-8 (P = 0.01) and HBD1 (P = 0.007) were higher than in those 
women who tested negative. In women who tested positive for Peptostreptococcus micros the median concen-
tration of HBD1 (P = 0.0005) was higher than in women who tested negative. Median levels of HBD1 were also 
higher in women who tested positive for Group B streptococcus (P = 0.0005) and Ureaplasma parvum (P = 0.01) 
than women who tested negative. No other differences were observed (Table 6).
Placental pathology. Placentas from 28 (66.4%) preterm and 35 (38.1%) term deliveries were available for 
histological examination (Table 1). A higher proportion of placental samples from women who delivered preterm 
showed signs of both chorioamnionitis and other placental pathology (P = 0.0001, Fisher’s exact test). In the 
women who delivered <37 weeks 20% (5/25) showed no placental pathology, 44% (11/25) had chorioamnionitis 
and 36% (9/25) other placental pathologies. In the women who delivered at term, 43% (15/35) showed no placen-
tal pathology, 28.5% (10/35) had some degree of chorioamnionitis and 28.5% (10/35) other placental pathologies.
Irrespective of pregnancy outcome, IL-8 levels were lower in the chorioamnionitis group compared to those 
without placental pathology (P = 0.03; Fig. 3A). There was no association between the presence of any species of 
bacterium and placental pathology (data not shown) or between the number of different detectable species and 
placental pathology (Fig. 3B).
Variable
Delivery <33 
weeks (n = 17)
Delivery 33–36 + 6 
weeks (n = 27)
Delivery ≥37 
weeks (n = 90)
Age (years), mean (range) 29 (20–39) 30.1 (22–39) 30.9 (17–44)
BMI (kg/m2), mean (range) 24.7 (17–37) 26.3 (19–38) 26.7 (19–52)
Ethnicity, n (%)
White European 17 (100) 26 (96.3) 86 (95.5)
White/black Caribbean 0 (0) 0 (0) 1 (1.1)
Asian-British 0 (0) 0 (0) 1 (1.1)
Indian 0 (0) 1 (3.7) 1 (1.1)
Other – Philipino 0 (0) 0 (0) 1 (1.1)
Smoking status, n (%)
Yes 9 (52.9) 7 (25.9) 18 (20.0)
No 8 (47.1) 21 (77.8) 71 (78.9)
Not known 0 (0) 0 (0) 1 (1.1)
Parity, mean (range) 1.8 (0–6) 1.8 (0–4) 1.4 (0–7)
Gestational age of previous PTB (completed weeks), mean (range) 29.3 (24–35) 31.3 (24–35) 31.0 (24–36)
Previous cervical surgery, n (%)
Yes 5 (29.4) 3 (11.1) 36 (40.0)
No 12 (70.6) 24 (88.9) 54 (60.0)
Randomised to Opptimum trial, n (%)
Yes 3 (17.6) 5 (18.5) 17 (18.9)
No 14 (82.4) 22 (81.5) 73 (81.1)
Gestational age at delivery (completed weeks), mean (range) 29.1 (25–32) 35.0 (33–36) 39.0 (37–42)
Table 3. Demographics of patients included in the analysis based on pregnancy outcome.
Risk factor Preterm delivery Term delivery P Valuea
IL-8 Previous PTB and/or Cervical Surgery (n = 95) 991.8 (1221.3; 29.8–10963.2) 1472.4 (1710.9; 287.5–13347.2) 0.03
IL-1β Previous PTB and/or Cervical Surgery (n = 95) 35.6 (78.0; 0.9–2097.9) 66.7 (190.8; 2.1–2523.1) 0.04
Elafin Previous PTB and/or Cervical Surgery (n = 132) 1349.4 (2973.5; 31.6–19285.3) 792.2 (2137.1; 16.7–104485.2) 0.1
hBD1 Previous PTB and/or Cervical Surgery (n = 132) 342.8 (542.1; 24.6–23431.3) 259.6 (321.5; 17.9–7431.2) 0.2
Table 4. Median (IQR; range) levels for cytokines, elafin and human beta defensin 1 (pg/mg protein). 
aComparison between PTB and term birth for each cytokine or antimicrobial, Mann-Whitney U test, 
significance at P < 0.05.
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Discussion
This study demonstrated a reduction in the level of IL-8 and IL-1 β in CVF taken at 22–24 weeks gestation from 
high-risk asymptomatic women who subsequently delivered preterm compared with women who delivered at 
term. In addition, women who delivered preterm had a greater bacterial load than those who delivered at term.
Our finding of reduced IL-8 and IL-1β supports several previous studies but is in disagreement with oth-
ers32,42–46. Cervical IL-8 and IL-1β (8–20 weeks gestation) were lowered in women who subsequently developed 
clinical chorioamnionits42. Women with low IL-1β and/or IL-8 and potentially pathological vaginal microflora 
had an increased risk of preterm birth, although reduced cytokines alone were not associated with PTB43. In addi-
tion, women with a high anti-inflammatory/low pro-inflammatory stratum in the first trimester had an increased 
risk of delivering before 34 weeks gestation43. In contrast, no change in CVF levels of IL-8 or IL-1β were reported 
prior to cervical shortening in women at high risk of sPTB45 and in another study a higher percentage of women 
with increased cervical mucus IL-8 levels at 20–24 weeks gestation delivered preterm compared with those with 
Figure 1. (A) Levels of IL-8 (pg/mg protein) in cervical fluid in women with previous PTB and/or cervical 
surgery (<37 weeks, n = 44; >37 weeks, n = 90). (B) Levels of IL-1β (pg/mg protein) in cervical fluid in women 
with previous PTB and/or cervical surgery (<37 weeks, n = 44; >37 weeks, n = 90).
Bacterium species
Birth 
outcome % (n)
Difference in 
proportions
95% CI of 
difference P valuea
Fusobacterium species
PTB 24.1 (7)
12.2% −4.2–32.5 0.1
Term 11.9 (10)
Peptostreptococcus micros
PTB 51.7 (15)
27.9% 6.0–48.6 0.005
Term 23.8 (20)
Group B streptococcus
PTB 27.5 (8)
18.0% 0.97–38.4 0.02
Term 9.5 (8)
Mycoplasma hominis
PTB 17.2 (5)
7.7% −6.4–27.0 0.3
Term 9.5 (8)
Ureaplasma urealyticum
PTB 27.5 (8)
−9.4% −12.8–28.0 0.4
Term 36.9 (31)
Ureaplasma parvum
PTB 27.5 (8)
15.6% −1.7–36.2 0.05
Term 11.9 (10)
Table 5. Spontaneous preterm birth rates in women with cervicovaginal samples positive for each bacterium 
species tested. PTB = preterm birth; CI = confidence interval. aComparison between PTB and term birth for 
each bacterial species (proportion of positive samples), Chi-Squared test, significance at P < 0.05.
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normal IL-8 levels46. Elevated antenatal vaginal levels of IL-8 and IL-1β in high risk women who delivered pre-
term compared to those delivering at term have also been reported, with IL-8 being an independent predictor 
of sPTB32. Reduced levels of cytokines within the lower genital tract in early pregnancy could indicate a broad 
immune hyporesponsiveness and an attenuated ability to mount an ‘appropriately vigorous’ response to infec-
tion35. Thus reduced maternal cervical immunity could lead to an environment more conducive to the ascent of 
pathogens into the choriodecidua, increasing susceptibility to chorioamnionitis35,43. Indeed, we also found an 
association between reduced cervical IL-8 levels and chorioamnionitis.
Cervical elafin levels have also not been found to be consistently altered in high risk women who deliver 
preterm47–49. One study found no correlation between CVF levels of elafin at 20–23 + 6 weeks gestation and 
subsequent sPTB, which is in agreement with the findings of the present study47. In contrast, reduced CVF elafin 
Figure 2. Bacterial species specific PCR for Fusobacterium species, Peptostreptococcus micros, Group B 
streptococcus, Mycoplasma hominis, Ureaplasma urealyticum and Ureaplasma parvum were carried out on 
samples collected between 22 and 24 weeks (n = 113). The proportion of women with samples positive for 
none of the bacteria (n = 33), one species (n = 46), two species (n = 17), three species (n = 10) and four species 
(n = 7) delivering preterm is represented by the grey portion of the bar. The proportion of women delivering 
at term is represented by the black portion of the bar. The proportion of women with samples positive for four 
species delivering preterm (71.4%) was significantly higher than that of the women with samples negative for all 
samples tested (21.42%, P = 0.009; Bonferroni alpha = 0.0125).
Bacterium species Bacterium status IL-8 IL-1β Elafin HBD1
Fusobacterium species
Positive 2093.5 (360.0–13347.2; n = 17) P = 0.01a 37.7 (2.5–2523.1; n = 17)
1165.7 (36.1–104485.2; 
n = 17)
442.6 (41.0–7431.2; n = 17) 
P = 0.007
Negative 678.8 (32.2–4187.8; n = 34) 32.6 (0.9–482.2; n = 34) 870.8 (16.7–19285.3; n = 70) 241.8 (17.9–2376.2; n = 70)
Peptostreptococcus micros
Positive 1162.9 (50.3–13347.2; n = 21) 49.2 (2.5–2523.1; n = 21 922.8 (26.6–104485.2; n = 31)
442.6 (24.6–7431.2; n = 31) 
P = 0.0005
Negative 638.1 (32.3–4187.8; n = 30) 17.0 (0.9–482.2; n = 30) 902.6 (16.7–19285.3; n = 56) 214.6 (17.9–2376.2; n = 56)
Group B streptococcus
Positive 1463.5 (331.2–2673.3; n = 14) 40.9 (4.0–482.2; n = 14) 854.6 (27.7–4491.7; n = 16) 508.9 (149.7–3382.4; n = 16) P = 0.0005
Negative 648.1 (32.3–13347.2; n = 37) 34.9 (0.9–2523.1; n = 37) 903.3 (16.7–104485.2; n = 71) 237.8 (17.9–7431.2; n = 71)
Mycoplasma hominis
Positive 493.2 (50.3–3012.3; n = 7) 50.5 (2.5–340.2; n = 7) 771.9 (95.31–4431.3; n = 10) 345.6 (24.6–3382.4; n = 10)
Negative 1104.3 (32.3–13347.2; n = 44) 33.3 (0.9–2523.1; n = 44) 903.3 (16.7–104485.2; n = 77) 262.8 (17.9–7431.2; n = 77)
Ureaplasma urealyticum
Positive 370.8 (32.2–2111.7; n = 9) 82.0 (0.9–482.2; n = 9) 621.0 (16.7–7255.9; n = 27) 199.6 (24.6–1009.2; n = 27)
Negative 1265.7 (62.0–3507.4; n = 36) 28.5 (2.1–2523.1; n = 36) 1077.7 (26.6–13799.5; n = 54) 302.4 (17.9–2376.2; n = 54)
Ureaplasma parvum
Positive 1591.7 (360.0–3507.4; n = 15) P = 0.002 50.5 (2.5–2173.9; n = 15) 922.8 (26.6–7255.9; n = 17)
422.8 (41.0–1098.8; n = 17) 
P = 0.01
Negative 536.9 (32.3–3029.7; n = 30) 28.4 (0.9–2523.1; n = 30) 784.1 (16.7–13799.5; n = 64) 214.6 (17.9–2376.2; n = 64)
Table 6. Cytokine and antimicrobial levels (Median, range) in bacterium species positive and negative samples. 
aComparison of cytokine or antimicrobial levels in women positive or negative for each bacterial species, Mann-
Whitney U test, significance at P < 0.01.
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levels have been reported in women with bacterial vaginosis at less than 20 weeks gestation, while another study 
reported increased second trimester CVF elafin levels in high risk women with a short cervix and subsequent 
sPTB48,49.
The different findings in cytokine and elafin levels compared with some (but not all) other studies may be 
explained by differences in the gestational ages of sample collection, sampling methodology, measurement meth-
odology, indication for study inclusion, and outcome measure. They may also reflect different genetic polymor-
phisms that have been reported for IL-1β and elafin48,50–53.
Previous work investigating human beta defensins and sPTB has focused on amniotic fluid levels, with second 
trimester HBD2 levels reported to be associated with preterm premature rupture of membranes, but not with 
preterm labor54. In this study cervical HBD1 levels were not altered in women delivering preterm compared with 
those delivering at term, and cervical HBD2 and HBD3 were not detected.
Women with cervicovaginal samples positive for Peptostreptococcus micros or Group B streptococcus and 
women with increasing numbers of potentially pathogenic bacterial species were more likely to deliver preterm. 
These species are frequently detected in membrane and placental samples from women delivering preterm, and 
a similar association has been demonstrated between increasing number of bacterial species detected in fetal 
membranes and preterm birth15. While Group B streptococcus and Ureaplasma parvum are not associated with 
BV, Peptostreptococcus micros, Mycoplasma hominis, Fusobacterium species and Ureaplasma urealyticum have all 
been described as BV associated bacteria55. Recent studies suggest an association between increased diversity of 
bacterial species in the vagina and PTB and the induction of the pro-inflammatory cytokines IL-1β, IL-6, IL-8, 
and TNF-α, which are known mediators of cervical remodeling56,57. In the current cohort we report increased 
IL-8, IL-1β and HBD1 levels in women positive for Fusobacterium species, Peptostreptococcus micros, Group B 
streptococcus and Ureaplasma parvum, and reduced levels of IL-8 and HBD1 in women positive for Ureaplasma 
urealyticum, but due to relatively low sample numbers pregnancy outcome was not taken into consideration in 
this analysis. In the current study we report a reduction in levels of IL-1β and IL-8 in women who deliver preterm. 
We also demonstrate an association between microflora load and pre-term birth, with those women positive for 
4 or more different bacterium species being more likely to deliver pre-term than those with no positive sample. 
However, there was no association between cytokine, or antimicrobial, levels and number of positive species (data 
not shown). The explanation for this dichotomy in results is unclear and a much larger cohort would be needed 
to tease out the relative importance of these different factors.
Figure 3. Association between placental pathology and (A) biomarker levels (IL-1β, IL-8, Elafin, hBD-1); and 
(B) 0–1, 2–3 or 4–5 different bacterial species present in cervical fluid.
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In this cohort of high risk women there was a high level of placental pathology irrespective of gestation at 
delivery, although the rate of placental pathology was higher in the group that delivered preterm compared with 
those who delivered at term. These data may reflect a susceptibility of these women to placental infection and 
damage. Inflammation was staged and graded according to Redline criteria39 and some women had early stage 
maternal and/or fetal inflammation such as subchorionitis or chorioinic vasculitis. In addition, lowered cervical 
fluid IL-8 levels were associated with chorioamnionitis irrespective of gestation at delivery, suggesting that low-
ered cervical antimicrobial defenses are associated with ascending infection and placental pathology, even if these 
features do not always lead to preterm birth. We might therefore postulate that ascending infection and placental 
pathology alone are not enough to cause preterm birth and that the uterine response and/or severity of infection/
placental pathology are more important indicators of whether a woman will deliver preterm or not.
A strength of this study is that the CVF was collected at an early gestational age (20–22 weeks), and therefore 
marker levels were not influenced by confounding factors such as uterine contractions during labor. This time 
was chosen as it fits with routine care visits within the UK and does not require women to attend the hospital for 
a non-scheduled visit. We utilised multiplex arrays when measuring cytokine levels, allowing for the concurrent 
measurement of numerous cytokines from the small CVF samples obtained. The major limitation of our study 
was that it was under powered to allow the outcome of earlier pre-term delivery (<33 weeks gestation) to be 
considered separately. In addition, not all samples were available for analysis in all of the different assays; due 
to freezer failure (microflora analysis), and limited sample volume and multiplex kit size (cytokine analysis). 
Biomarker levels varied substantially with large overlaps between outcome groups and hence our study was too 
small to produce prediction statistics, a larger replication cohort is required. The microflora study was exploratory 
and needs to also be repeated with a larger cohort and non-biased analytical methodology. A small number of 
women in the study were also included in a randomised controlled trial of vaginal progesterone (OPPTIMUM: 
ISRCTN14568373)58 and it is possible that, in those taking active drug, this impacted on outcome, although no 
effect of progesterone on outcome was reported59.
In conclusion, we have demonstrated that patients with a history of prior sPTB and/or prior cervical surgery 
who deliver preterm, have reduced second trimester CVF IL-8 and IL-1β levels prior to onset of sPTB symp-
toms. Women with four or more bacterial species in the cervix were more likely to deliver preterm. Further 
studies are required to understand the complex relationship between host antimicrobial protein expression and 
the mucosal cervical microflora. In addition, much larger studies are needed to assess whether these biomarkers 
independently or collectively improve prediction of sPTB in women with a history of sPTB, especially given the 
large variation in CVF cytokine levels which does not allow for predictive cut-off levels to be determined.
References
 1. Mathews, T. J., Menacker, F. & MacDorman, M. F. Centers for Disease Control and Prevention, National Centre for Health Statistics. 
Infant mortality statistics from the 2002 period: linked birth/infant death data set. Natl Vital Stat Rep. 53, 1–29 (2004).
 2. Goldenberg, R. L., Culhane, J. F., Iams, J. D. & Romero, R. Epidemiology and causes of preterm birth. Lancet. 371, 75–84 (2008).
 3. Office for National Statistics. Gestation specific infant mortality in England and Wales, 2009. Statistical bulletin. Oct 2011.
 4. World Health Organisation, Preterm birth, fact sheet No 363, Geneva WHO (2013).
 5. Langhoff-Roos, J., Kesmodel, U., Jacobsson, B., Rasmussen, S. & Vogel, I. Spontaneous preterm delivery in primiparous women at 
low risk in Denmark: population based study. BMJ. 332, 937–9 (2006).
 6. Romero, R., Dey, S. K. & Fisher, S. J. Preterm labor: one syndrome, many causes. Science. 345, 760–5 (2014).
 7. Romero, R. et al. The role of infection in preterm labor and delivery. Paediatr Perinat Epidemiol. 15, 41–56 (2001).
 8. Yoon, B. H. et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J 
Obstet Gynaecol. 185, 1130–6 (2001).
 9. Goldenberg, R. L., Hauth, J. C. & Andrews, W. W. Intrauterine infection and preterm delivery. N Engl J Med. 342, 1500–7 (2000).
 10. Nguyen, D. P., Gerber, S., Hohlfeld, P., Sandrine, G. & Witkin, S. S. Mycoplasma hominis in mid-trimester amniotic fluid: relation to 
pregnancy outcome. J Perinat Med. 32, 323–6 (2004).
 11. Cahill, R. J. et al. Universal DNA primers amplify bacterial DNA from human fetal membranes and link Fusobacterium nucleatum 
with prolonged preterm membrane rupture. Mol Hum Reprod. 11, 761–6 (2005).
 12. Witt, A. et al. Increased intrauterine frequency of Ureaplasma urealyticum in women with preterm labor and preterm premature 
rupture of the membranes and subsequent cesarean delivery. Am J Obstet Gynaecol. 193, 1663–9 (2005).
 13. Kataoka, S. et al. Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. J Clin Microbiol. 
44, 51–5 (2006).
 14. Han, Y. W., Shen, T., Chung, P., Buhimschi, I. A. & Buhinschi, C. S. Uncultivated bacteria as etiologic agents of intra-amniotic 
inflammation leading to preterm birth. J Clin Microbiol. 47, 38–47 (2009).
 15. Jones, H. E. et al. Differing prevalence and diversity of bacterial species in fetal membranes from very preterm and term labor. PLoS 
One. 4, e8205 (2009).
 16. Romero, R. et al. Infection and labor. VIII. Microbial invasion of the amniotic cavity in patients with suspected cervical 
incompetence: prevalence and clinical significance. Am J Obstet Gynaecol. 167, 1086–91 (1992).
 17. McManemy, J., Cooke, E., Amon, E. & Leet, T. Recurrence risk for preterm delivery. Am J Obstet Gynaecol. 196, 576e1–576.e7 
(2007).
 18. Noehr, B., Jensen, A., Frederiksen, K., Tabor, A. & Kjaer, S. K. Depth of cervical cone removed by loop electrosurgical excision 
procedure and subsequent risk of spontaneous preterm delivery. Obstet Gynaecol. 114, 1232–8 (2009).
 19. Iams, J. D. et al. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and 
Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynaecol. 178, 1035–1040 (1998).
 20. Leitich, H. et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynaecol. 189, 139–47 (2003).
 21. Nathan, C. & Sporn, M. Cytokines in context. J Cell Biol. 113, 981–986 (1991).
 22. Hiemstra, P. S. et al. Antibacterial activity of antileukoprotease. Infect Immun. 64, 4520–4 (1996).
 23. Simpson, A. J., Maxwell, A. I., Govan, J. R., Haslett, C. & Sallenave, J. M. Elafin (elastase-specific inhibitor) has anti-microbial activity 
against gram-positive and gram-negative respiratory pathogens. FEBS Lett. 452, 309–13 (1999).
 24. King, A. E., Kelly, R. W., Sallenave, J. M., Bocking, A. D. & Challis, J. R. Innate immune defences in the human uterus during 
pregnancy. Placenta. 28, 109–106 (2007).
 25. Rizzo, G. et al. Interleukin-6 concentrations in cervical secretions identify microbial invasion of the amniotic cavity in patients with 
preterm labor and intact membranes. Am J Obstet Gynaecol. 175, 812–7 (1996).
1 0Scientific RepoRtS |         (2019) 9:11246  | https://doi.org/10.1038/s41598-019-47756-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
 26. Rizzo, G. et al. Ultrasonographic assessment of the uterine cervix and interleukin-8 concentrations in cervical secretions predict 
intrauterine infection in patients with preterm labor and intact membranes. Ultrasound Obstet Gynaecol. 12, 86–92 (1998).
 27. Kekki, M. et al. Insulin-like growth factor-binding protein-1 in cervical secretion as a predictor of preterm delivery. Acta Obstet 
Gynecol Scand. 80, 546–51 (2001).
 28. Lembet, A. et al. New rapid bed-side test to predict preterm delivery: phosphorylated insulin-like growth factor binding protein-1 
in cervical secretions. Acta Obstet Gynecol Scand. 81, 706–12 (2002).
 29. Jacobsson, B. et al. Monocyte chemotactic protein-1 in cervical and amniotic fluid: relationship to microbial invasion of the amniotic 
cavity, intra-amniotic inflammation, and preterm delivery. Am J Obstet Gynecol. 189, 1161–7 (2003).
 30. Tromp, G. et al. Genome-wide expression profiling of fetal membranes reveals a deficient expression of proteinase inhibitor 3 in 
premature rupture of membranes. Am J Obstet Gynaecol. 191, 1331–8 (2004).
 31. King, A. E. et al. Expression of natural antimicrobials by human placenta and fetal membranes. Placenta. 28, 161–9 (2007).
 32. Raiche, E., Ouellet, A., Berthiaume, M., Rousseau, É. & Pasquier, J. C. Short and inflamed cervix predicts spontaneous preterm birth 
(COLIBRI study). J Matern Fetal Neonatal Med. 27, 1015–9 (2014).
 33. Goepfert, A. R. et al. The Preterm Prediction Study: association between cervical interleukin 6 concentration and spontaneous 
preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet 
Gynaecol. 184, 483–8 (2001).
 34. Honest, H., Bachmann, L. M., Gupta, J. K., Kleijnen, J. & Khan, K. S. Accuracy of cervicovaginal fetal fibronectin test in predicting 
risk of spontaneous preterm birth: systematic review. BMJ. 325, 301 (2002).
 35. Kuhrt, K., Hezelgrave, N. H., Foster, C., Seed, P. T. & Shennan, A. H. Development and validation of a tool incorporating 
quantitiative fetal fibronectin to predict spontaneous preterm birth in asymptomatic women. Ultrasound Obstet Gynecol. 47, 210–6 
(2016).
 36. Whitworth, M. K., Pafilis, I., Vince, G. & Quenby, S. Cervical leukocyte sub-populations in idiopathic preterm labour. J Reprod 
Immunol. 75, 48–55 (2007).
 37. Lash, G. E. et al. Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight and FAST Quant. J Immunol 
Methods. 309, 205–8 (2006).
 38. Lash, G. E. & Pinto, L. A. Multiplex cytokine analysis technologies. Expert Rev Vaccines. 9, 1231–7 (2010).
 39. Redline, R. W. et al. Amniotic infection syndrome: nosology and reproducibility of placental reaction patterns. Pediatr Dev Pathol. 
6, 435–48 (2003).
 40. Redline, R. W. et al. Maternal vascular underperfusion: nosology and reproducibility of placental reaction patterns. Pediatr Dev 
Pathol. 7, 237–49 (2004).
 41. Stanek, J. Hypoxic patterns of placental injury: a review. Arch Pathol Lab Med. 137, 706–20 (2013).
 42. Simhan, H. N. et al. Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during 
pregnancy. Am J Obstet Gynecol. 189, 560–7 (2003).
 43. Kalinka, J., Sobala, W., Wasiela, M. & Brzezińska-Blaszczyk, E. Decreased proinflammatory cytokines in cervicovaginal fluid, as 
measured in midgestation, are associated with preterm delivery. Am J Reprod Immunol. 54, 70–6 (2005).
 44. Simhan, H. N. & Krohn, M. A. First-trimester cervical inflammatory milieu and subsequent early preterm birth. Am J Obstet 
Gynaecol. 200(377), e1–4 (2009).
 45. Chandiramani, M. et al. Limited relationship between cervico-vaginal fluid cytokine profiles and cervical shortening in women at 
high risk of spontaneous preterm birth. PLoS One. 7, e52412 (2012).
 46. Sakai, M. et al. Evaluation of effectiveness of prophylactic cerclage of a short cervix according to interleukin-8 in cervical mucus. Am 
J Obstet Gynaecol. 194, 14–9 (2006).
 47. Bastek, J. A. et al. Biomarkers and cervical length to predict spontaneous preterm birth in asymptomatic high-risk women. Obstet 
Gynaecol. 122, 283–9 (2013).
 48. Stock, S. J. et al. Elafin (SKALP/Trappin-2/proteinase inhibitor-3) is produced by the cervix in pregnancy and cervicovaginal levels 
are diminished in bacterial vaginosis. Reprod Sci. 16, 1125–34 (2009).
 49. Abbott, D. S. et al. Raised trapin2/elafin protein in cervico-vaginal fluid is a potential predictor of cervical shortening and 
spontaneous preterm birth. PLoS One. 9, e100771 (2014).
 50. Genc, M. R. et al. Polymorphism in intron 2 of the interleukin-1 receptor antagonist gene, local midtrimester cytokine response to 
vaginal flora, and subsequent preterm birth. Am J Obstet Gynaecol. 19, 1324–30 (2004).
 51. Schmid, M. et al. Interleukin-1 beta gene polymorphisms and preterm birth. Eur J Obset Gynaecol Reprod Biol. 165, 33–6 (2012).
 52. Tribe, R. M. Small peptides with a Big Role: Antimicrobial Peptides in the Pregnant Female Reproductive Tract. Am J Reprod 
Immunol. 74, 123–5 (2015).
 53. Tejera, P. et al. Genetic polymorphisms of peptidase inhibitor 3 (elafin) are associated with acute respiratory distress syndrome. Am 
J Respir Cell Mol Biol. 41, 696–704 (2009).
 54. Iavazzo, C. et al. The role of human beta defensins 2 and 3 in the second trimester amniotic fluid in predicting preterm labor and 
premature rupture of membranes. Arch Gynecol Obstet. 281, 793–9 (2010).
 55. Malaguti, N., Bahls, L. D., Uchimura, N. S., Gimenes, F. & Consolaro, M. E. Sensitive Detection of Thirteen Bacterial Vaginosis-
Associated Agents Using Multiplex Polymerase Chain Reaction. Biomed Res Int. 2015, 645853 (2015).
 56. DiGiulio, D. B. et al. Temporal and spatial variation of the human microbiota durig pregnancy. Proc Natl Acad Sci USA 112, 11060–5 
(2015).
 57. Kindinger, L. M. et al. Relationship between vaginal microbial dysbiosis, inflammation, and pregnancy outcomes in cervical 
cerclage. Sci Transl Med. 8, 350ra102 (2016).
 58. Norman, J. E. et al. Trial protocol OPPTIMUM—does progesterone prophylaxis for the prevention of preterm labour improve 
outcome? BMC Pregnancy Childbirth. 12, 79 (2012).
 59. Norman, J. E. et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-
blind trial. Lancet. 387, 2106–2116 (2016).
Acknowledgements
The authors wish to thank all patients who took part in this study. We would also like acknowledge the research 
midwifery team at the Royal Victoria Infirmary, Newcastle upon Tyne for their assistance with sample collection. 
This project was supported by funding from Wellbeing of Women (ELS027) and The Wellcome Trust (RTF 
WT097228MA).
Author Contributions
G.E.L., C.P.J., J.N.B., S.C.R., D.M.P., N.K. and M.B.E. designed the study; C.P.J. analysed data and carried 
out the PCRs; G.E.L., B.A.I. and C.P.J. carried out multiplex analysis and ELISAs; G.E.L. carried out the total 
protein assays; J.N.B. performed the placental pathology; R.M., E.S. and G.E.L. analysed the data and wrote the 
manuscript; R.M., M.C.S. and S.C.R. recruited patients and collected clinical data; B.A.I. oversaw all biobanking 
of samples. All authors contributed to the manuscript.
1 1Scientific RepoRtS |         (2019) 9:11246  | https://doi.org/10.1038/s41598-019-47756-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Additional information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
